SC
NBIX icon

Samlyn Capital’s Neurocrine Biosciences NBIX Stock Holding History

Samlyn Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-192,325
Closed -$18.5M – 182
2020
Q3 		$18.5M Buy
+192,325
New +$22.2M 0.33% 76
2019
Q3 		– Sell
-387,897
Closed -$32.8M – 133
2019
Q2 		$32.8M Buy
+387,897
New +$31.8M 0.69% 54
2017
Q2 		– Sell
-92,983
Closed -$4.03M – 142
2017
Q1 		$4.03M Buy
+92,983
New +$3.98M 0.09% 126
2016
Q3 		– Sell
-168,000
Closed -$7.64M – 135
2016
Q2 		$7.64M Buy
+168,000
New +$7.73M 0.18% 87

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Samlyn Capital's NBIX Position: Q4 2020 in Review

Samlyn Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 192,325 shares — an estimated $18.5M sold.

Samlyn Capital first reported a position in NBIX in Q2 2016 and held it in 4 quarters. The position peaked at $32.8M in Q2 2019. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Samlyn Capital reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Samlyn Capital sold 192,325 Neurocrine Biosciences shares in Q4 2020, an estimated $18.5M.
  • Samlyn Capital first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 4 quarters.
  • Samlyn Capital's Neurocrine Biosciences position peaked at $32.8M in Q2 2019.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Samlyn Capital's 13F filing for Q4 2020, filed 16 Feb 2021.